共 62 条
[1]
Shea M(2016)Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches Ther Adv Respir Dis 10 113-129
[2]
Costa DB(2015)Nivolumab in NSCLC: latest evidence and clinical potential Ther Adv Med Oncol 7 85-96
[3]
Rangachari D(2016)Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 16 275-287
[4]
Sundar R(2010)Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma J Mol Med (Berl) 88 817-827
[5]
Topalian SL(2009)Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 Mol Cancer Ther 8 1702-1713
[6]
Daskalow K(2018)Increased lactate secretion by Cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies Cell Metab 28 848-865
[7]
Sullivan R(2008)Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers Clin Cancer Res 14 6963-6973
[8]
Graham CH(2016)The emerging hallmarks of Cancer metabolism Cell Metab 23 27-47
[9]
Apicella M(2013)Targeting cellular metabolism to improve cancer therapeutics Cell Death Dis 4 571-600
[10]
Yonesaka K(2015)Cancer metabolism and drug resistance Metabolites 5 39-1249